Analysts Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $23.00

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have been assigned a consensus rating of "Reduce" from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $23.00.

A number of analysts have recently commented on the stock. Bank of America dropped their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a report on Monday, October 7th. BTIG Research upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price for the company. Truist Financial dropped their price target on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Finally, Citigroup raised their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday, November 5th.

Integra LifeSciences Stock Up 0.9 %

IART traded up $0.21 on Wednesday, hitting $22.68. The company had a trading volume of 331,094 shares, compared to its average volume of 1,042,292. The stock has a fifty day simple moving average of $22.93 and a 200-day simple moving average of $23.00. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm has a market capitalization of $1.75 billion, a P/E ratio of -251.97, a P/E/G ratio of 0.82 and a beta of 1.15. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the business posted $0.76 EPS. As a group, equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IART. Versor Investments LP purchased a new stake in shares of Integra LifeSciences in the 3rd quarter worth $612,000. BNP Paribas Financial Markets grew its holdings in Integra LifeSciences by 824.5% during the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock valued at $2,031,000 after purchasing an additional 99,685 shares during the period. GSA Capital Partners LLP purchased a new stake in Integra LifeSciences in the third quarter worth about $960,000. Point72 Europe London LLP lifted its position in shares of Integra LifeSciences by 13.8% during the 2nd quarter. Point72 Europe London LLP now owns 546,035 shares of the life sciences company's stock valued at $15,911,000 after buying an additional 66,400 shares in the last quarter. Finally, Public Sector Pension Investment Board bought a new position in shares of Integra LifeSciences during the 2nd quarter valued at approximately $4,395,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.